论文部分内容阅读
1998年5月22日,上海市心脑血管病防治研究办公室和中美上海施贵宝制药有限公司联合举办了“普拉固新适应证新闻发布会”。会上,主办单位宣布了一条在医学史上具有重大意义的信息:普拉固能有效地预防中风和冠心病。 普拉固又名普伐他汀,是一种他汀类降胆固醇药。普拉固对于血胆固醇正常的冠心病患者,能降低中风和一过性脑缺血(小中风)的发生率;并且对于上述患者能减少心肌梗塞再发和心脏病所致的死亡。上述两点结论已于1998年获得美国最高药品审批机构——美国FDA的批准。这是第一个他汀类药物在上述人群中获这些适应证。 上海市心脑血管病防治研究办公室主任、神经内科
On May 22, 1998, Shanghai Cardiovascular and Cerebrovascular Disease Research Office and Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. jointly held a press conference on the Pulaud new indications. At the meeting, the organizers announced a message of great significance in the history of medicine: Pulavir can effectively prevent stroke and coronary heart disease. Pravastatin, also known as pravastatin, is a statin cholesterol-lowering drug. Prasugrel reduces the incidence of stroke and transient cerebral ischemia (stroke) in patients with stable CHD and reduces the risk of recurrent heart attacks and heart-related deaths in these patients. The above two conclusions were obtained in 1998 by the United States FDA, the highest drug approval agency in the United States. This is the first statin to receive these indications in these populations. Shanghai Cardiovascular Disease Prevention Research Office Director, Department of Neurology